article ban

mccomb title two

References
Note: Links to citations open in a new browser window.  To return to this page, just close the newly opened browser window by clicking on the X in the upper right hand corner of the window.

  1. Ernst E.  Herbal medications for common ailments in the elderly.  Drugs Aging.  1999 Dec;15(6):423-8.

  2. Borchers AT, Keen CL, Stern JS, Gershwin ME.  Inflammation and Native American medicine: the role of botanicals.  Am J Clin Nutr.  2000 Aug;72(2):339-47.  Review.

  3. Melchart D, Walther E, Linde K, Brandmaier R, Lersch C.  Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial.  Arch Fam Med.  1998 Nov-Dec;7(6):541-5.

  4. National Toxicology Program.   "Echinacea: treatment or prevention?" Health News 1999;5:7.

  5. Cunningham JJ.  Micronutrients as nutriceutical interventions in diabetes mellitus.  J Am Coll Nutr.  1998 Feb;17(1):7-10.  Review.

  6. Heiligenstein E, Guenther G.  Over-the-counter psychotropics: a review of melatonin, St John's wort, valerian, and kava-kava.  J Am Coll Health.  1998 May;46(6):271-6.

  7. Fetrow CW, Avila JR.  The Complete Guide to Herbal Medicine, Springhouse Corporation, Springhouse, PA, 2000.

  8. Smolinske SC.  Dietary supplement-drug interactions.  J Am Med Womens Assoc.  1999 Fall;54(4):191-2,195.  Review.

  9. Fugh-Berman A.  Herb-drug interactions.  Lancet.  2000 Jan 8;355(9198):134-8.  Review.

  10. O'Hara M, Kiefer D, Farrell K, Kemper K.  A review of 12 commonly used medicinal herbs.  Arch Fam Med.  1998 Nov-Dec;7(6):523-36.  Review.

  11. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H.  Inhibition of monoamine oxidase by hypericin.  Planta Med.  1984 Jun;50(3):272-4.  No abstract available.

  12. Wong AH, Smith M, Boon HS.  Herbal remedies in psychiatric practice.  Arch Gen Psychiatry.  1998 Nov;55(11):1033-44.  Review.

  13. Walter G, Rey JM.  The relevance of herbal treatments for psychiatric practice.  Aust N Z J Psychiatry.  1999 Aug;33(4):482-9; discussion 490-3.  Review.

  14. Kamuhabwa AR, Roelandts R, de Witte PA.  Skin photosensitization with topical hypericin in hairless mice.  J Photochem Photobiol B.  1999 Nov-Dec;53(1-3):110-4.

  15. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, Meehan P, Hussey S, Forcht J, Valentine FT.  Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults.  AIDS Clinical Trials Group Protocols 150 and 258.  Ann Intern Med.  1999 Mar 16;130(6):510-4.

  16. Hudson JB, Delaey E, de Witte PA.  Bromohypericins are potent photoactive antiviral agents.  Photochem Photobiol.  1999 Nov;70(5):820-2.

  17. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Law RE, Apuzzo ML, Law RE.  Hypericin: a potential antiglioma therapy.  Neurosurgery.  1994 Oct;35(4):705-9; discussion 709-10.

  18. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A .  Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells.  Photochem Photobiol.  1996 Aug;64(2):375-81.

  19. VanderWerf QM, Saxton RE, Chang A, Horton D, Paiva MB, Anderson J, Foote C, Soudant J, Mathey A, Castro DJ.  Hypericin: a new laser phototargeting agent for human cancer cells.  Laryngoscope.  1996 Apr;106(4):479-83.

  20. Rose H, Wagner H.  The effect of hypericin as a sensitizer of biological systems against visual and ionizing radiation.  Radiobiol Radiother 1965;6(4):477-83.

  21. Bladt S, Wagner H.  Inhibition of MAO by fractions and constituents of hypericum extract.  J Geriatr Psychiatry Neurol.  1994 Oct;7 Suppl 1:S57-9.

  22. Bennett DA Jr, Phun L, Polk JF, Voglino SA, Zlotnik V, Raffa RB.  Neuropharmacology of St. John's Wort (Hypericum).  Ann Pharmacother.  1998 Nov;32(11):1201-8.  Review.

  23. Thiede HM, Walper A.  Inhibition of MAO and COMT by hypericum extracts and hypericin.  J Geriatr Psychiatry Neurol.  1994 Oct;7 Suppl 1:S54-6.

  24. Gordon J.  SSRI's and St. John's wort: Possible toxicity? Am Fam Phys 1998;57:28-32.

  25. Demott K.  St. John's wort tied to serotonin syndrome.  Clin Psychiatry News 1998;26:28-29.

  26. Lantz MS, Buchalter E, Giambanco V.  St. John's wort and antidepressant drug interactions in the elderly.  J Geriatr Psychiatry Neurol.  1999 Spring;12(1):7-10.

  27. Sternbach H.  The serotonin syndrome.  Am J Psychiatry.  1991 Jun;148(6):705-13.  Review.

  28. Boudikova-Girard B, Scott MC, Weinshilboum R.  Histamine N-methyltransferase: inhibition by monoamine oxidase inhibitors.  Agents Actions.  1993 Sep;40(1-2):1-10.

  29. Feighner JP.  Mechanism of action of antidepressant medications.  J Clin Psychiatry.  1999;60 Suppl 4:4-11; discussion 12-3.  Review.

  30. Jappe U, Franke I, Reinhold D, Gollnick HP.  Sebotropic drug reaction resulting from kava-kava extract therapy: a new entity?  J Am Acad Dermatol.  1998 Jan;38(1):104-6.  No abstract available.

  31. Uebelhack R, Franke L, Schewe HJ.  Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava).  Pharmacopsychiatry.  1998 Sep;31(5):187-92.

  32. Muller B, Komorek R.  [Treatment with Kava--the root to ocombat stress].  Wien Med Wochenschr.  1999;149(8-10):197-201.  Review.  German.

  33. Baum SS, Hill R, Rommelspacher H.  Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats.  Prog Neuropsychopharmacol Biol Psychiatry.  1998 Oct;22(7):1105-20.

  34. Scherer J.  Kava-kava extract in anxiety disorders: an outpatient observational study.  Adv Ther.  1998 Jul-Aug;15(4):261-9.

  35. Seitz U, Schule A, Gleitz J.  [3H]-monoamine uptake inhibition properties of kava pyrones.  Planta Med.  1997 Dec;63(6):548-9.

  36. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH.  St John's Wort: effect on CYP3A4 activity.  Clin Pharmacol Ther.  2000 May;67(5):451-7.

  37. Obach RS.  Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression.  J Pharmacol Exp Ther.  2000 Jul;294(1):88-95.

  38. Conney A.  Induction of microsomal cytochrome P-450 enzymes: the first Bernard B. Brodie lecture at Pennsylvania State University.  Life Sci.  1986 Dec 29;39(26):2493-518.  Review.  No abstract available.

  39. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G.  Acute heart transplant rejection due to Saint John's wort.  Lancet.  2000 Feb 12;355(9203):548-9.

  40. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J.  Indinavir concentrations and St John's wort.  Lancet.  2000 Feb 12;355(9203):547-8.

  41. Baede-van Dijk PA, van Galen E, Lekkerkerker JF.  [Drug interactions of Hypericum perforatum (St. John's wort) are potentially hazardous].  Ned Tijdschr Geneeskd.  2000 Apr 22;144(17):811-2.  Review.  Dutch.

  42. Lan LB, Dalton JT, Schuetz EG.  Mdr1 limits CYP3A metabolism in vivo.  Mol Pharmacol.  2000 Oct;58(4):863-9.

  43. Mayhew BS, Jones DR, Hall SD.  An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.  Drug Metab Dispos.  2000 Sep;28(9):1031-7.

  44. Budzinski JW, Foster BC, Vandenhoek S, Arnason JT.  An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures.  Phytomedicine.  2000 Jul;7(4):273-82.

  45. Mashour NH, Lin GI, Frishman WH.  Herbal medicine for the treatment of cardiovascular disease: clinical considerations.  Arch Intern Med.  1998 Nov 9;158(20):2225-34.  Review.

  46. Neil HA, Silagy CA, Lancaster T, Hodgeman J, Vos K, Moore JW, Jones L, Cahill J, Fowler GH.  Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis.  J R Coll Physicians Lond.  1996 Jul-Aug;30(4):329-34.

  47. Isaacsohn JL, Moser M, Stein EA, Dudley K, Davey JA, Liskov E, Black HR.  Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial.  Arch Intern Med.  1998 Jun 8;158(11):1189-94.

  48. Silagy CA, Neil HA.  A meta-analysis of the effect of garlic on blood pressure.  J Hypertens.  1994 Apr;12(4):463-8.

  49. Bordia A.  Effect of garlic on human platelet aggregation in vitro.  Atherosclerosis.  1978 Aug;30(4):355-60.

  50. Rahman K, Billington D.  Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans.  J Nutr.  2000 Nov;130(11):2662-5.

  51. Grontved A, Hentzer E.  Vertigo-reducing effect of ginger root.  A controlled clinical study.  ORL J Otorhinolaryngol Relat Spec.  1986;48(5):282-6.

  52. Langner E, Greifenberg S, Gruenwald J.  Ginger: history and use.  Adv Ther.  1998 Jan-Feb;15(1):25-44.  Review.

  53. Backon J.  Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry.  Med Hypotheses.  1986 Jul;20(3):271-8.  Review.

  54. Backon J.  Ginger as an antiemetic: possible side effects due to its thromboxane synthetase activity.  Anaesthesia.  1991 Aug;46(8):705-6.  No abstract available.

  55. Cott J.  NCDEU update.  Natural product formulations available in europe for psychotropic indications.  Psychopharmacol Bull.  1995;31(4):745-51.  Review.

  56. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF.  A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia.  North American EGb Study Group.  JAMA.  1997 Oct 22-29;278(16):1327-32.

  57. Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ.  Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man.  Lancet.  1987 Jan 31;1(8527):248-51.

  58. Rowin J, Lewis SL.  Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion.  Neurology.  1996 Jun;46(6):1775-6.  No abstract available.

  59. Liberti LE, Der Marderosian A.  Evaluation of commercial ginseng products.  J Pharm Sci.  1978 Oct;67(10):1487-9.

  60. Herbal Roulette.  Consumer Reports 1995;698-705.

  61. Sotaniemi EA, Haapakoski E, Rautio A.  Ginseng therapy in non-insulin-dependent diabetic patients.  Diabetes Care.  1995 Oct;18(10):1373-5.

  62. Janetzky K, Morreale AP.  Probable interaction between warfarin and ginseng.  Am J Health Syst Pharm.  1997 Mar 15;54(6):692-3.  No abstract available.

  63. Miller LG.  Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions.  Arch Intern Med.  1998 Nov 9;158(20):2200-11.  Review.

  64. Cupp MJ.  Herbal remedies: adverse effects and drug interactions.  Am Fam Phys.  1999 Mar 1;59(5):1239-45.  Review.

  65. Hopkins MP, Androff L, Benninghoff AS.  Ginseng face cream and unexplained vaginal bleeding.  Am J Obstet Gynecol.  1988 Nov;159(5):1121-2.

  66. Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC.  Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats.  J Pharm Pharmacol.  1999 Feb;51(2):175-80.

  67. Wustenberg P, Henneicke-von Zepelin HH, Kohler G, Stammwitz U.  Efficacy and mode of action of an immunomodulator herbal preparation containing Echinacea, wild indigo, and white cedar.  Adv Ther.  1999 Jan-Feb;16(1):51-70.  Review.

  68. Sun LZ, Currier NL, Miller SC.  The American coneflower: a prophylactic role involving nonspecific immunity.  J Altern Complement Med.  1999 Oct;5(5):437-46.

  69. Rehman J, Dillow JM, Carter SM, Chou J, Le B, Maisel AS.  Increased production of antigen-specific immunoglobulins G and M following in vivo treatment with the medicinal plants Echinacea angustifolia and Hydrastis canadensis.  Immunol Lett.  1999 Jun 1;68(2-3):391-5.

  70. See DM, Broumand N, Sahl L, Tilles JG.  In vitro effects of echinacea and ginseng on natural killer and antibody-dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients.  Immunopharmacology.  1997 Jan;35(3):229-35.

  71. Brinkeborn RM, Shah DV, Degenring FH.  Echinaforce and other Echinacea fresh plant preparations in the treatment of the common cold.  A randomized, placebo controlled, double-blind clinical trial.  Phytomedicine.  1999 Mar;6(1):1-6.

  72. Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, Wagner H.  Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea.  J Altern Complement Med.  1995 Summer;1(2):145-60.

  73. Barrett B, Vohmann M, Calabrese C.  Echinacea for upper respiratory infection.  J Fam Pract.  1999 Aug;48(8):628-35.  Review.

  74. Blumenthal M, Gruenwald J, et al., Eds. (1998).  German Commision E Monographs:  Therapeutic monographs on medicinal plants.  Austin, TX, American Botanical Council.

  75. Kaatz B.  Phenytoin suppositories and echinacea.  S D J Med.  1997 Sep;50(9):335.  No abstract available.

  76. Borbas A, Janossy L, Liptak A.  Scope and limitation of the application of the (methoxydimethyl)methyl group in the synthesis of 2'-O-, 6'-O- and 2',6'-di-O-(alpha-L-arabinofuranosyl)-beta-D-galactopyranosyl- (1-->6)-D-galactoses.  Carbohydr Res.  1999 May 31;318(1-4):98-109.

  77. Wagner H, Breu W, et al.  In vitro inhibition of arachidonate metabolism by some alkamides and prenylated phenols.  Planta Med 1989;55:  566-567.

  78. Muller-Jakic B, Breu W, Probstle A, Redl K, Greger H, Bauer R.  In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from Echinacea and Achillea species. Planta Med.  1994 Feb;60(1):37-40.

  79. Vavreckova C, Gawlik I, Muller K.  Benzophenanthridine alkaloids of Chelidonium majus; I.  Inhibition of 5- and 12-lipoxygenase by a non-redox mechanism.  Planta Med.  1996 Oct;62(5):397-401.

  80. Belch JJ, Hill A.  Evening primrose oil and borage oil in rheumatologic conditions.  Am J Clin Nutr.  2000 Jan;71(1 Suppl):352S-6S.  Review.

  81. Horrobin DF.  Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren's syndrome.  Med Hypotheses.  1984 Jul;14(3):233-47.

  82. Ziboh VA, Miller CC, Cho Y.  Metabolism of polyunsaturated fatty acids by skin epidermal enzymes: generation of antiinflammatory and antiproliferative metabolites.  Am J Clin Nutr.  2000 Jan;71(1 Suppl):361S-6S.  Review.

  83. Manthorpe R, Hagen Petersen S, Prause JU.  Primary Sjogren's syndrome treated with Efamol/Efavit.  A double-blind cross-over investigation.  Rheumatol Int.  1984;4(4):165-7.

  84. Scimore A.  US sees the green in herbal supplements.  Chem Market Rep 1998;(254):  FR 3-4.

    85.
Page 23 of 24
Citation Number:
Vol. 2, No. 2, Page 023